Эффективность и безопасность противовирусной терапии ВИЧ-инфекции и хронического гепатита С у больных сочетанной инфекцией
Диссертация
Актуальность проблемы. Широкое распространение ВИЧ-инфекции на территории России начиная с 1998 г. было обусловлено проникновением вируса в среду потребителей инъекционных наркотиков (ПИН). К концу 2010 г. более чем у 500 тысяч жителей Российской Федерации установлен диагноз ВИЧ-инфекции. В 56,2% случаев заражение вирусом иммунодефицита человека (ВИЧ) произошло при внутривенном введении… Читать ещё >
Список литературы
- Бобкова М.Р. Генетические варианты вируса гепатита С у ВИЧ-инфицированных наркоманов / М. Р. Бобкова, Е. И. Самохвалова, A.B. Кравченко и др.// Вопр. Вирусол.-2002.- Т. 17. № 3.- С. 15−20.
- Бобкова М.Р. Молекулярно-генетические методы в изучении эпидемиологии инфекций, возбудители которых передаются парентеральным путем // Автореф. дисс. докт. биол. наук. М., 2002.44 с.
- Громова Н.И. Эффективность противовирусной терапии у больных хр. Гепатитом С. Протекающим с нормальным уровнем АЛТ. // Инфекционные болезни. 2011. — № 4. — С.5−10.
- Иванова Л.М. Комбинированная терапия хронического гепатита С пегилированным интерфероном альфа-2а и рибавирином у ВИЧ-инфицированных пациентов. Автореф. дис. канд. мед. наук. М., 2007.
- Канестри В.Г. Комбинированная противовирусная терапия хронического гепатита С у больных ВИЧ-инфекцией: Дис. канд. мед. наук. М.: 2001.
- Канестри В.Г. Гепатотоксичность у больных ВИЧ-инфекцией, получавших антиретровирусную терапию. / В. Г. Канестри, A.B. Кравченко, Н. Ю. Ганкина и др. // Эпидемиология и инфекционные болезни. 2006. — № 6, — С. 31−34.
- Кравченко A.B. Особенности антиретровирусной терапии при сочетании ВИЧ-инфекции и хронического вирусного гепатита / A.B. Кравченко, Н. Ю. Ганкина, В. Г. Канестри //Фарматека, 2008.-№ 19.-С.10−17.
- Кравченко А.В. Сочетанное лечение ВИЧ-инфекции и вирусных гепатитов//Медицинская Кафедра. 2003 № 1 (5). — С. 30−40.
- Ладная Н.Н. Развитие эпидемии ВИЧ-инфекции в регионах Российской Федерации в 2007 г. / H. Н. Ладная, Е. В. Соколова, О. Г. Юрин, А. В. Кравченко и соавт. // Эпидемиология и инфекционные болезни. 2008. — № 3. — С. 7−12.
- Максимов С.Л. Особенности терапии хронического гепатита С пегилированным интерфероном-а2А и рибавирином у больных ВИЧ-инфекцией. / С. Л. Максимов, Л. И. Иванова, А. В. Кравченко и др. // Терапевтический архив. -2007. № 79(11).- Р.40−4.
- Покровский В.В. ВИЧ-инфекция и СПИД национальное руководство/под ред. акад. РАМН В. В. Покровского.- М.: ГЭОТАР-Медиа, 2013. С. 36,69.
- Покровский В. В. ВИЧ/СПИД в России: ситуация и прогноз / В. В. Покровский // Эпидемиология и инфекционные болезни. 2008. — № 3 -С. 4−7.
- Резолюция Первой Европейской согласительной конференции по лечению хронических гепатитов В и С у ВИЧ-инфицированных. Стандарты медицины. 2006- № 1: С.39−48.
- Юрин Ю.Г. Никавир новый отечественный противовирусный препарат / Юрин О. Г., Афонина Л. Ю., и соавт. // Эпидемиология и инфекционные болезни. — 2001. — № 1. — С. 43−45.
- Alberti A. Management of hepatitis С. / A. Alberti, L. Benvegnu // Journal of Hepatology — 2003. 38(Suppl). — S.104-S118.
- Alberti A. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. /A. Alberti, N. Clumeck, S. Collins, et al.// J Hepatol.- 2005.-42.- P.615−624.
- Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. / MJ. Alter// J Hepatol. 2006. — 44(Suppl) — S6−9. doi: 10.1016/j .jhep.2005.11.004.
- Alvarez D. Short statement of the first European Consensus Conference on the treatment of chronic Hepatitis B and C co-infected patients. / D. Alvarez, DT. Dieterich, S. Collins, et al. // J Hepatol. 2005. — № 42. — P. 615 — 24.
- Anand B.S. Assessment of correlation between serum titers of hepatitis c virus and severity of liver disease. / BS. Anand, M. Velez // World Journal of Gastroenterology. 2004. — 10(16). — P. 2409−12 411.
- Benhamou Y. Liver fibrosis progression in HIV and HCV coinfected patients. / Y. Benhamou, M. Bochet, V. Di Martino, et al. // Hepatology. -1999.-30. -P. 1054−8.
- Bjornsson E. Suspected drug-induced liver fatalities reported to the WHO database. /E. Bjornsson, R. Olsson // Dig Liver Dis. 2006.-№ 38-P.33−8.
- Brau N. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy./ N. Brau, M. Salvatore, C. Rios-Bedoya, et al.// J Hepatol. 2006. — 44. — P.47−55.
- Brau N. Treatment of chronic hepatitis C in HIV/HCV-coinfection with IFNa-2b plus ribavirin full-course vs. 16-week delayed ribavirin. N. Brau, M. Rodriguez-Torres, D. Prokupek, et al. // Hepatology. 2004.-№ 39.-P.989−98.
- Brinker Den M. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. / Den Brinker M, Wertheim-van Dillen PM, et al. // AIDS. 2000. — № 14(18). — P.2895−2902.
- Buti M. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C/ M. Buti, MA. Casado, L. Fosbrook, et al.// J Hepatol -2000.-№ 33-P. 651−8.
- Carr A. Lactic academia in infection with HIV. Clin Infect Dis. 2003.-№ 36- S96-S100.
- Carrat F. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIVinfected patients: a randomized controlled trial./ F. Carrat, F. Bani-Sadr, S. Pol et al.// JAMA 2004. — P. 292, 2839−2848.
- Chelsea B. Polis. Impact of Material HIV Coinfection on the Vertical Transmission of Hepatitis C Virus: A Meta-analysis. / CB Polis, SN. Shah, KE. Johnson, and A. Gupta // CID. 2007. — № 44. — P. 1121 — 1131.
- Chan-Tack KM. Atazanavir-associated nephrolithiasis cases from the US Food and Drug Administration’s Adverse Event Reporting System. / KM. Chan-Tack, MM. Truffa, KA. Struble K, et al. // AIDS. 2007. — № 21. -1215−8.
- Chung R.T. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-infected persons. / R.T. Chung, J. Andersen, O. Volberdin, et al. // N. Engl. J. Med. 2004. — 351,451−459.
- Clark SJ. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. / SJ. Clark, Creighton, B. Portmann, et al. // J. Hepatol. 2002. — № 36 — P. 295−301.
- Crespo M. Pegylated interferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-coinfected persons / M. Crespo, S. Sauleda, J.L. Esteban et al.// J. Viral Hepat. 2006.- 14- P. 228−238.
- Daar E.S. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. / E.S. Daar, H. Lynn, S. Donfield et al.//J. Infect. 2001. — 183 — P. 589−595.
- Dienstag JL. American Gastroenterological Association medical position statement on the management of hepatitis C. / J.L. Dienstag, J. G McHutchison. Gastroenterology. 2006. — 130. — P.225−230.
- Dieterich D. Effect of baseline CD4% on the efficacy of PEG-IFNa-2a plus ribavirin-findings from the APRICOT. / D. Dieterich, M. Opravil, J. Sasadeusz, et al. // 46 ICAAC, San Francisco, September 2006 abstract H-1888.
- European AIDS Clinical Society. Version 6.1-November 2012.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatis C virus infection. J. Hepatology. 2011.
- European AIDS Clinical Society Issues New Guidelines for Treatment of HIV// lllh annual EACS conference in Madrid, Spain.-2007.- October 2427.
- Ferenei P. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response/ P. Ferenci et al.// Gastroenterology 135(2): 2008. P. 451−458.
- Ferenci P. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin./ P. Ferenci, MW. Fried, ML. Shiffman, et al. //J Hepatol.- 2005.-№ 43(3).-P.425−433.
- Fishbein D.A. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. / D.A. Fishbein, E. Lo, D. Netski, et al.// J. Acquir. Immune Defic. Syndr. 2006.-41.- P. 471−476.
- Franciscus A. HCV Diagnostic Tools: Genotype, Subtype & Quasispecies./A. Franciscus// HCSP Fact Sheet. 2010. — 2(2).-P.l-3.
- Fried M.W. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. / M. W. Fried, M.L. Shiffman, K.R. Reddy et al.// N Engl J Med.-2002.-347.-P.975−982.
- Gao B. Host factors and failure of IFN treatment in HCV. / B. Gao, F. Hong, S. Radaeva. // Hepatology. 2004. — № 39. — P. 880−90.
- Garcia-Samaniego J. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. / J. Garcia-Samaniego, M. Rodriguez, J. Berenguer, et al.// Am. J. Gastroenterol.- 2001. 183. — P. 589−595.
- Ge D. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance./ D. Ge, J. Fellay, A.J. Thompson, et al. // Nature. 2009. -Vol. 461.-P. 399−401.
- Gotz HM. A cluster of acute hepatitis C virus infection among men who have sex with men-results from contact tracing and public health implications./ HM. Gotz, van G. Doornum, HG. Niesters, et al.// AIDS.-2005.-19-P. 969−74.
- Graham C.S. Influence of Human Immunodeficiency Virus Infection on the Course of Hepatitis C Virus Infection: A Meta-Analysis./ C.S. Graham, L.R.Baden, E. Yu, J.M. Mrus, J. Carnie, T. Heeren, and M.J. Koziel//CID 2001.-33-P.562.
- Hoffmann C. and J.K. Rockstroh. HIV 2011.-P. 504−505.
- Jen J. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Glue P, Gupta S, Zambas D, Hajian G. //Ther Drug Monit. 2000.- № 22.- P. 555−65.
- Jensen D.M. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alfa-2a (40kd)/ ribavirin therapy. D.M. Jensen, T.R. Morgan, P. Marcellin, et al. // Hepatology.- 2006.-№ 43.-P. 954−960.
- Johnson LB. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. / LB. Johnson, LD. Saravolatz. // Clin Infect Dis.-2009.-№ 48.-P. 1121−8.
- Kanazawa Y. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients/ Y. Kanazawa, N. Hayashi, E. Mita et al.// Hepatol. 1994. — V.20. — P. 1121.
- Khaykin P. Impact of different ART regimens on efficacy and safety of standard HCV treatment in HTV/HCV co-infected patients. / P. Khaykin, M. Vogel, E. Voigt, et al. // 4th IAS Conference on HIV Pathogenesis,
- Treatment and Prevention. 22−25 July 2007, Sydney. Australia.-Abstr. MOPEB056.
- Kim A. The magnitude and breadth of HCV-specific CD8 T-cells depend on absolute CD4 T-cell count in individuals coinfected with HIV-1/ A. Kim, G. Lauer et al.// Blood.- 2005.- 105 P. 1170−8.
- Klein MB. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. MB. Klein, RG. Lalonde, S. Suissa. // J Acquir Immune Defic Syndr. 2003.- № 33 (3).-P.365−372.
- Laguno M. Peginterferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. / M. Laguno, J. Murillas, J.L. Blanco, et al.//AIDS.-2004.-18.-F27-F36.
- Landau A. Long-term efficacy of combination therapy with interferon alfa-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. A Landau, D. Batisse, C. Piketty, et al. AIDS.-2001. № 15.-P. 2149−2155.
- Lee SS. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. / SS. Lee, P. Ferenci.// Antivir The 2008, — 13 Suppl 1: 9−16.
- Lin CY. IL28B SNP rs 12 979 860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. / CY. Lin, JY. Chen, TN. Lin, et al. // PLos 0ne.-2011. № 6 (3):el8322.
- Lindahl K. High-dose ribavirin in combination with standard dose PEG-IFN for treatment of patients with chronic hepatitis C./ K. Lindahl, L. Stahle, A. Bruchfeld, R. Schvarcz.//Hepatology.-2005.- №.41-P.275−9.
- Mallolas J. Nevirapine-associated hepatotoxicity in virologically suppressed patients-role of gender and CD4+ cell counts. AIDS Rev. 2006. — № 8.-P.238−9.
- Mark S. Hepatitis B and C virus co-infection and the risk for hepatotoxicity active antiretroviral therapy in HIV-1 infection./ S. Mark, S. Sulkowsky, David L. Thomas, Richard E. Chaisson, Richard D. Moore.//JAMA.-2000.-283(1).-P .74−80.
- Martin-Cabonero L. Icidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C a European collaborative study. /L. Martin-Cabonero, Y. Benhamou, M. Puoti, et al.// Clin Infect Dis.-2004.- 38.- P.128−33.
- Martinez-Sierra C. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with HCV and HIV. / C. Martinez-Sierra, A. Arizcorreta, F. Diaz, et al. // Clin Infect Dis. 2003. — 36. — P.491−8.
- Mauss S. Risk factors for hepatic decompensation in patients with HCV/HIV coinfection and liver cirrhosis during interferon-based therapy./S. Mauss, W. Valenti, J. DePamphillis, et al. // AIDS.-2004.-№ 18. F21−25.
- Mauss S. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4 cell count./S. Mauss, H. Klinker H, A. Ulmer, et al. // Infection. 1998. — № 26. — P. 16−19.
- Maylin S. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. / S. Maylin, M. Martinot-Peignoux, R. Moucari, et al. //Gastroenterology.-2008.- 135 (3).-P.821−829.
- Mehta S. The effect of antiretroviral therapy on liver disease among adults with HIV and HCV coinfection ./ S. Mehta, D. Thomas, M. Torbenson, et al.//Hepatology.- 2005,-41. -P.123−31.
- Merchante N. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HTVYHCV coinfected patients. J Hepatol 2008- 50 (2009): P. 684−692.
- McHutchison JG. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. / J.G. McHutchison, M.P. Manns, R.S. Brown, K.R. Reddy, M.L. Shiffman, J.B. Wong. // Am J Gastroenterol.- 2007.-102.-P.880−889.
- McHutchison J. Peginterferon-alfa2b or alfa-2a with ribavirin for treatment of hepatitis C infection. J. McHutchison, E. Lawitz, M. Shiffman, et al.//N. Engl. J. Med.- 2009. 361(6). — P. 580−593.
- Mocroft A. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. / A. Mocroft, B. Ledergerber, Kadama, et al.//Lancet-2003.- 362,22−29.
- Moreno A. High rate of didanosine-related mitochondrial toxicity in HCV/HIV coinfected patients receiving ribavirin. / A. Moreno, C. Quereda, L. Moreno, MJ. Perez-Elias, A. Muriel, JL. Casado, et al. Antivir Ther. 2004. -№ 9(1).-P. 133−8.
- Moyle J.G. Viral coinfections in HIV. / J.G. Moyle, J.P. Lalezari J.P.//Chicago, Remedica, 2008. P. 176.
- National Institute of Health. National Institute of Health consensus development conference statement: management of hepatitis C: 2002, June 1012. Hepatology. 2002.- 36: S3−20.
- Nunez M. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial / M. Nunez, C. Miralles, M.A. Berdum et al. // AIDS Res. Human Retroviruses-2007. № 23.- P.972−982.
- Nunez M. Risk factors for severe hepatic injury following the introduction of HAART. / M. Nunez, R. Lana, J. Mendoza, L. Martin-Cabonero, V. Soriano.// J Acquir Immun Defic Syndr. 2001 .-27. — P.426−31.
- Nunez M. Impact of ribavirin exposure on early virologic response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C./ M. Nunez, N. Camino, B. Ramos, et al. //Antivir Ther.- 2005.-№ 10.-P. 657−62.
- Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management./ M. Nunez, V. Soriano.// Drug Saf.- 2005.-№ 28.- P.53−66.
- Qurishi N. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and HCV coinfection./ N. Qurishi, C. Kreuzberg, G. Luchters, et al.// Lancet.- 2003.- 362.-P.1708−13.
- Perez-01meda M. Virologic characteristics of HCV infection in HIV-infected individuals with chronic hepatitis C: implications for treatment./ M. Perez-Olmeda, P. Rios, M. Nunez, J. Garcia-Samaniego, M. Romero, V. Soriano// AIDS 2002. — № 16 — P.493−5.
- Pesce A. Opportunistic infections and CD4 lymphocytopenia with IFN treatment in HIV-1 infected patients. A. Pesce, B. Taillan, E. Rosenthal.// Lancet. 1993.-341: 1597.
- Pol S. Changing distribution of HCV genotypes in Europe in the last decades. /S. Pol, V. Thiers, J. Nousbaum, et al.// J Hepatol. 1994. — 21 (Suppl):13.
- Rauch A. Genetic variation in IL28B is associated with chronic Hepatitis C and treatment failure: a genome-wide association study. / A. Rauch, Z. Kutalik, P. Descombes, et al. //Gastroenterology. 2010. — Vol. 138. — P.1338−1348.
- Rendon A. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/HCV-coinfected patients. A. Rendon, M. Nunez, M. Romero, et al.// L Acquir Immune Defic Syndr.-2005.№ 39.-P.401−405.
- Romero-Gomez M. Insulin resistance impairs sustained response rate to PEG- IFN plus ribavirin in chronic hepatitis C patients. M. Romero-Gomez M. Del, R. Andrade, et al. // Gastroenterology. 2005, — 128: P.636−41.
- Salmon-Ceron D. Liver disease as a major cause of death among HIV infected patients: role of hepatitis-C and -B viruses and alcohol. / D. Salmon-Ceron, C. Lewden, P. Morlat, et al. // J. Hepatol. 2005. — № 42(6). — P.799−805.
- Sanne I. Severe hepatotoxicity associated with nevirapine use in HIV-infected Subjects. /1. Sanne, H. Mommeja-Marin, J. Hinkle, et al. // J. Infect Dis.-2005.-191. P.825−829.
- Servoss JC, Kitch DW, Andersen JW et al. Predictors of antiretroviral-related hepatotoxicity JC, Kitch DW, Andersen JW et al. Predictors of antiretroviral-Immune Defic Syndr2006- 1- 43: 320−3.
- Sherman K.E. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections./ K.E. Sherman, J. O’Brien, A.G. Gutierrez et al. // J. Clin. Microbiol. 1993. — 31. — P.2679−2682.
- Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and HCV: 2007 Updated recomendation from the HCV-HIV International Panel. AIDS. 2007. — № 2. — P. 1073−89.
- Stattermayer AF. Impact of IL 28B genotype on the early and sustained virologic response in treatment-na'ive patients with chronic hepatitis C. / AF. Stattermayer, Stauber, H. Hofer, et al. // Clin Gastroenterol Hepatol. 2011.-9(4):344−350 e 2.
- DB. Diagnosis, management, and treatment of hepatitis C. / D.B. Strader, T. Wright, D.L. Thomas, L.B. Seeff./ Hepatology.- 2004.-№ 39.-P. 1147−1171.
- Sulkowski M. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. / M. Sulkowski, D. Thomas, R. Chaisson, R. Moore. // JAMA. 2000. — 283. P.74−80.
- Sulkowski M.S. Hepatotoxicity associated Nevirapine or Efavirenz-containing antiretroviral therapy: role of hepatitis B and C Infection. / M.S. Sulkowski, D.L. Thomas, S.H.Mehta, et al. // Hepatology. 2002.-№ 35,-P.182−9.
- Suppiah V. IL28B is associated with response to chronic hepatitis C interferon alpha and ribavirin therapy./ V. Suppiah, M. Moldovan, G. Ahlenstiel, et al.// Nat. Genet. — 2009. — Vol.41. — P. 1100−1104.
- Tanaka Y. Genome-wide association of IL28B with response to pegylated interferon- alpha and ribavirin therapy for chronic hepatitis C. / Y. Tanaka, N. Nishida, M. Sugiyama, et al //Nat. Genet. 2009. — Vol.41.- P. 1105−1109.
- The Global Burden of Hepatitis C Working Group. Global burden of desease for hepatitis C. J Clin Pharmacol. 2004. — 44.-P.20−9.
- Thomas D. The natural history of HCV infection: host, viral, and environmental factors. / D. Thomas, J. Astemborski, R. Rai, et al. // JAMA.-2000. 284:450−6.
- Thomas D.L. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. / D.L. Thomas, J.W. Shih, H.J. Alter et al.//J. Infect. Dis. 1996.-174.-P. 690−695.
- Thomas D.L. Determinants of the quantity of hepatitis C virus RNA./D.L. Thomas, J. Astemborski, D. Vlahov, et al.// J. Infect. Dis. 2000. — 181. -P.844−851.
- Torriani F.J. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.// F.J. Torriani, M. Rodriguez-Torres, J.K. Rockstroh et al.// N. Engl. J. Med. 2004. — P. 351, 438−450.
- Torriani F.J. Chronic hepatitis C in HIV-infected individuals. / F.J. Torriani, V. Soriano// AIDS Rev. 2000. — 2. — P. 168−177.
- Tural C. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and HCV coinfected patients. / C. Tural, D. Fuster, J. Tor, et al. // J Viral Hepat.-2003.-10. P. 118−25.
- Vachon M-L.C. HCV Treatment Challenges in Patients Co-infected with HIV. / M-L.C. Vachon, N. Qazi, D.T. Dieterich. // Future HIV Ther. 2009. -№ 3(1). -P.87−100.
- Vallet-Pichard A. Natural history and predictors of severity of chronic hepatitis C virus and human immunodeficiency virus coinfection./ A. Vallet-Pichard, S. Pol//J. Hepatol. 2006. — 44 (Suppl. 1) — S28-S34.
- Vento S. Rapid decline of CD4 cells after IFN treatment in HIV-1 infection. IS. Vento, G. Di Perri, M. Criciani, T. Garofano, E. Concia, D. Bassetti. // Lancet. 1993. -341:958−9.
- Vogel M. The burden of HIV and hepatitis C virus coinfection/ M. Vogel, F. Sauter, E. Voigt and J.K. Rockstroh.// HIV and viral hepatitis coinfection -2007.-P. 1−11.
- Vogel M. Pegylated interferon-a for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals/ M. Vogel, J. Nattermann, A. Baumgarten et al. // Antivir Ther. 2006. — P. 1097−101.
- Wasmuth JC. HIV and HBV/HCV Coinfections// JC. Wasmuth, J Rockstroh// HIV. -2009. P.486.
- Weber R. Liver-related deaths in persons infected with the human immunodeficiency virus: the DAD study. // R. Weber, CA Sabin, N. Friis-Moller, et al.// Arch. Intern. Med.-2006. 166(15). — P. 1632−1641.
- Zeuzem S. Heterogeneous virologic response rates to IFN-based therapy in patients with chronic hepatitis C: who responds less well?// Ann Intern Med. 2004.-140:370−81.